Eurice Supports Innovation in Diabetes Management with the MuSiC4Diabetes Project: Unobtrusive Continuous Diabetes Management Technology
Diabetes mellitus is a rapidly growing life-threatening disease. This condition affects the individual with a variety of symptoms, ranging from blurred vision and weight loss to disorders of the cardiovascular system, kidney, eye and nerves. The disease has dramatically increased over the last three decades, with a doubling of the number of affected people between 1980 and 2017, and this number is expected to rise to 629 million cases by 2045. Current diabetes management systems such as glucose monitoring systems and integrated insulin-delivery devices offer valuable treatment solutions. However, they require regular maintenance by the patient, and can fail to forecast glucose deficits in specific situations.
Eurice is proud to be a partner in the MuSiC4Diabetes project which will develop an implantable multi-metabolite sensor connected to a pump that delivers insulin continuously to the patient. This initiative aims to provide a long-lasting and unobtrusive solution to Type 1 diabetes patients by significantly extending the device’s autonomy and increasing its insulin capacity.
To achieve this ambitious step forward in diabetes management technology, the project will receive more than EUR 3.8 million from the prestigious European Innovation Council’s (EIC) Pathfinder programme over the next four years and benefit from the collaboration of six European partnering institutions.
"We are thrilled to be part of the MuSiC4Diabetes consortium and bring in our experience and strategic expertise when it comes to IP and exploitation management in this topic. Thus, we will help to bring the research results to relevant stakeholders and, ultimately, the patients. This is particularly significant as this is an EIC Pathfinder action with a distinct emphasis on Innovation and Exploitation Management, says Jörg Scherer, Eurice CEO.
With several Horizon 2020 and Horizon Europe projects in the field, Eurice has a strong track record in managing large-scale diabetes research endeavours and built up an extensive network in the scientific and medical diabetes community. In MuSiC4Diabetes, Eurice takes the lead of WP7 "Innovation management: Communication, dissemination, exploitation", concerting and leading all innovation related and communication activities, and will take an active role in stakeholder management activities.
